

**Amendments to the Specification:**

Please replace the paragraphs starting at page 1, line 3:

**[ACKNOWLEDGMENTS**

This invention was supported in part by grants from the National Institutes of Health grant number 1 R01 DK 43787 and 5 R01 DK 41842. The U.S. Government may have certain rights in this invention.

**CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims the benefit of the following provisional applications: United States Ser. No. 60/008,540 and 60/008,543, filed December 13, 1995, and Ser. No. 60/008,606, filed December 14, 1995. This application claims the benefit of the following U.S. patent application: United States Ser. No. 08/764,870, filed December 13, 1996.]  
with the following amended paragraphs:

**CROSS-REFERENCE TO RELATED APPLICATIONS**

This application claims priority to and benefit of prior U.S. Provisional Application number 60/008,540, filed December 13, 1995, prior U.S. Provisional Application number 60/008,543, filed December 13, 1995, and prior U.S. Provisional Application number 60/008,606, filed December 14, 1995. This application is a continuation of U.S. patent application 09/637,132, which is a divisional application of U.S. application number 08/980,115, which is a continuation in part of U.S. application number 08/764,870; priority to and benefit of each of which is claimed by this application. The full disclosures of each of these prior applications are incorporated herein by reference.

**ACKNOWLEDGMENTS**

This invention was supported in part by grants from the National Institutes of Health grant number 1 R01 DK 43787 and 5 R01 DK 41842. The U.S. Government may have certain rights in this invention.

Please replace the paragraph at page 6, line 3 [**FIG. 3** shows the aligned amino acid sequences of the ligand binding domains of several members of the nuclear receptor superfamily.]

with the following amended paragraph:

**FIGS. 3A-3R** show the aligned amino acid sequences of the ligand binding domains of several members of the nuclear receptor superfamily.

Please replace the paragraph at page 6, line 31 [**FIG. 14** is the synthetic scheme for preparation of TS10.]

with the following amended paragraph:

**FIGS. 14A-14B** show a synthetic scheme for preparation of TS10.

Please replace the paragraph at page 7, line 4 [**FIG. 17** depicts a Scatchard analysis of labelled T<sub>3</sub> binding to human TR- $\alpha$  and TR- $\beta$ .]

with the following amended paragraph:

**FIGS. 17A-17B** depict a Scatchard analysis of labeled T<sub>3</sub> binding to TR- $\alpha$  and TR- $\beta$ .